Edition:
United Kingdom

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

1.79USD
17 Aug 2018
Change (% chg)

$-0.03 (-1.65%)
Prev Close
$1.82
Open
$1.81
Day's High
$1.85
Day's Low
$1.79
Volume
4,361
Avg. Vol
20,005
52-wk High
$3.25
52-wk Low
$1.12

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Qtrly Loss Per Share $0.03
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS.AETERNA ZENTARIS INC - AT DECEMBER 31, 2017, WE HAD $7.8 MILLION OF CASH AND CASH EQUIVALENTS.AETERNA ZENTARIS- EXPECT EXISTING CASH BALANCES WILL PROVIDE WITH ADEQUATE FUNDS TO SUPPORT CURRENT OPERATING PLAN FOR AT LEAST NEXT TWELVE MONTHS.AETERNA ZENTARIS INC QTRLY LOSS PER SHARE $0.03.  Full Article

Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Strongbridge Biopharma Plc ::STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS.STRONGBRIDGE BIOPHARMA - ‍UNDER TERMS OF AGREEMENT, CO TO MAKE UPFRONT PAYMENT OF $24 MILLION TO AETERNA WITHIN 5 DAYS OF EFFECTIVE DATE OF AGREEMENT​.STRONGBRIDGE BIOPHARMA - LICENSE & ASSIGNMENT AGREEMENT ALSO PROVIDES CO WITH EXCLUSIVE LICENSE TO MANUFACTURE & COMMERCIALIZE MACRILEN IN U.S. & CANADA.STRONGBRIDGE BIOPHARMA PLC - STRONGBRIDGE EXPECTS TO COMMERCIALLY LAUNCH MACRILEN IN MID-YEAR 2018.STRONGBRIDGE BIOPHARMA PLC - ‍EXPANDS STRUCTURED FINANCING FACILITY WITH CRG TO SUPPORT ANTICIPATED COMMERCIAL LAUNCH OF MACRILEN IN MID-2018​.STRONGBRIDGE BIOPHARMA - AETERNA ZENTARIS WILL REMAIN RESPONSIBLE FOR A PEDIATRIC DEVELOPMENT PROGRAM TO SUPPORT REGULATORY SUBMISSION FOR MACRILEN APPROVAL.STRONGBRIDGE - ‍IN CONJUNCTION WITH MACRILEN DEAL, CO, CRG AMENDED EXISTING SENIOR CREDIT FACILITY TO INCREASE TOTAL POTENTIAL BORROWING TO $100 MILLION​.STRONGBRIDGE BIOPHARMA-CO SHARING OVERSIGHT AND PAYING FOR 70 PERCENT OF COST OF PEDIATRIC DEVELOPMENT PROGRAM OR ABOUT $4 MILLION OVER A 3-YEAR PERIOD​.STRONGBRIDGE - ‍UNDER AMENDED FACILITY, CO RETAINED OPTION TO BORROW ADDITIONAL $10 MILLION BASED UPON SOME CONDITIONS​.STRONGBRIDGE - ‍INTENDS TO USE UPFRONT PROCEEDS FROM SECOND BORROWING TO FUND ACQUISITON, COMMERCIALIZATION OF MACRILEN, CORPORATE PURPOSES​.  Full Article

Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS PROVIDES UPDATE ON LITIGATION AGAINST DAVID DODD AND PHILIP THEODORE.AETERNA ZENTARIS INC - CO AND ITS CHAIR CONSIDER COUNTERCLAIM AGAINST THEM TO BE "ENTIRELY WITHOUT MERIT".AETERNA ZENTARIS - IN RECEIPT OF A STATEMENT OF DEFENCE AND COUNTERCLAIM FILED BY FORMER OFFICERS DAVID DODD AND PHILIP THEODORE.AETERNA ZENTARIS - COUNTERCLAIM ALLEGES DEFAMATORY STATEMENTS IN RESPECT OF DODD, THEODORE WERE MADE IN A CO'S PRESS RELEASE & CLAIMS DAMAGES OF $6 MILLION.  Full Article

David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Aeterna Zentaris Inc ::DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS.DAVID DODD - DODD, FORMER CEO OF AETERNA ZENTARIS & PHILIP THEODORE, CO'S FORMER GENERAL COUNSEL, HAVE RESPONDED TO CLAIM FILED AGAINST THEM BY CO.DAVID DODD SAYS DODD & PHILIP THEODORE HAVE BROUGHT A COUNTERCLAIM AGAINST CO & ITS CHAIR, CAROLYN EGBERT, IN AMOUNT OF $6.0 MILLION.DAVID DODD - DODD AND THEODORE HAVE BROUGHT COUNTERCLAIM AGAINST CO AND ITS CHAIR, CAROLYN EGBERT, IN AMOUNT OF $6.0 MILLION.  Full Article

Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY.AETERNA ZENTARIS - INTENDS TO MAKE MACRILEN AVAILABLE COMMERCIALLY IN UNITED STATES DURING Q1 OF 2018.  Full Article

Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER.AETERNA ZENTARIS INC - DEPARTURE OF COMPANY'S INTERIM CHIEF FINANCIAL OFFICER, JEFFREY WHITNELL, EFFECTIVE DECEMBER 7, 2017.AETERNA ZENTARIS INC - COMMENCED A SEARCH FOR WHITNELL'S REPLACEMENT AS PRINCIPAL FINANCIAL OFFICER.  Full Article

Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY.AETERNA ZENTARIS INC - ‍MAA FOR USE OF MACRILEN FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY BEEN ACCEPTED BY EMA FOR REGULATORY REVIEW​.  Full Article

Aeterna Zentaris reports Q3 loss per share of $0.61
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris reports third quarter 2017 financial and operating results.Q3 loss per share $0.61.  Full Article

Aeterna Zentaris to pursue FDA registration of Macrilen
Monday, 13 Feb 2017 

Aeterna Zentaris Inc : Aeterna Zentaris announces plans to pursue FDA registration of Macrilen(tm) . FDA has agreed to consider company's conclusions during a type a meeting . Co concluded that macrilen demonstrated performance supportive of achieving registration with U.S. Food and drug administration . Aeterna Zentaris says co-primary endpoint "negative agreement" with itt, which is considered as more relevant endpoint, was met .Says co-primary endpoint "positive agreement" with itt was not met.  Full Article

Aeterna and Specialised Therapeutics Asia sign exclusive license agreement
Wednesday, 12 Oct 2016 

Aeterna Zentaris Inc : Aeterna Zentaris and Specialised Therapeutics Asia sign exclusive license agreement for the potential marketing of Zoptrex(TM) in Australia and New Zealand . Aeterna Zentaris Inc - company expects to complete phase 3 clinical trial for Zoptrex in 2016 . Aeterna Zentaris Inc - plans to submit a new drug application for Zoptrex(TM) to United States Food And Drug Administration (FDA) in first half of 2017 . Aeterna Zentaris - co to be entitled to receive non-refundable upfront payment in consideration for license to sta of co's IP related to Zoptrex(TM) . Aeterna Zentaris - entitled to non-refundable upfront payment in consideration allso for grant to STA of right to commercialize Zoptrex in territory . Aeterna Zentaris - STA has also agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones . Aeterna zentaris- STA has also agreed to make additional payments to co such as double-digit royalties on future net sales of Zoptrex(TM) in territory . Aeterna Zentaris - STA will be responsible for development, reimbursement, commercialization of product in territory (Australia, New Zealand) .Aeterna Zentaris Inc - supply agreement with STA pursuant to which company will supply zoptrex(TM) to sta for duration of license agreement.  Full Article

BRIEF-Aeterna Zentaris Reports Qtrly Earnings Per Share $0.87

* AETERNA ZENTARIS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS